Correspondence 0001193125-24-257051 from Ventyx Biosciences, Inc. (VTYX) (CIK 0001851194) (VTYX)
Ventyx Biosciences, Inc. (VTYX) (CIK 0001851194)
Date: Nov. 13, 2024 · CIK: 0001851194 · Accession: 0001193125-24-257051
AI Filing Summary & Sentiment
File numbers found in text: 333-283076
Letter
November 13, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3720
Attention: Alan Campbell
Re: Ventyx Biosciences, Inc. (the “Registrant”)
Registration Statement on Form S-3 (File No. 333-283076)
Request for Acceleration
Acceleration Request
Requested Date: November 15, 2024
Requested Time: 4:00 PM ET
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Ventyx Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-283076) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or at such later time as the Company or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Martin Waters at (858) 350-2308.
The Company understands that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the offering of the securities covered by the Registration Statement.
[Signature page follows]
Securities and Exchange Commission
November 13, 2024
Page 2
Sincerely,
VENTYX BIOSCIENCES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP November 13, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Alan Campbell Re: Ventyx Biosciences, Inc. (the “Registrant”) Registration Statement on Form S-3 (File No. 333-283076) Request for Acceleration Acceleration Request Requested Date: November 15, 2024 Requested Time: 4:00 PM ET Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Ventyx Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-283076) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or at such later time as the Company or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Martin Waters at (858) 350-2308. The Company understands that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the offering of the securities covered by the Registration Statement. [Signature page follows] Securities and Exchange Commission November 13, 2024 Page 2 Sincerely, VENTYX BIOSCIENCES, INC. /s/ Raju Mohan Raju Mohan Chief Executive Officer and President Enclosures cc: Roy Gonzales, Ventyx Biosciences, Inc. Austin Rutherford, Ventyx Biosciences, Inc. Martin J. Waters, Wilson Sonsini Goodrich & Rosati, P.C. Robert L Wernli, Jr., Wilson Sonsini Goodrich & Rosati, P.C.